EP4522735A1 - Utilisation de transposases pour améliorer l'expression transgénique et la localisation nucléaire - Google Patents

Utilisation de transposases pour améliorer l'expression transgénique et la localisation nucléaire

Info

Publication number
EP4522735A1
EP4522735A1 EP23726939.4A EP23726939A EP4522735A1 EP 4522735 A1 EP4522735 A1 EP 4522735A1 EP 23726939 A EP23726939 A EP 23726939A EP 4522735 A1 EP4522735 A1 EP 4522735A1
Authority
EP
European Patent Office
Prior art keywords
transposase
protein
nucleic acid
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23726939.4A
Other languages
German (de)
English (en)
Inventor
Avencia SÁNCHEZ-MEJÍAS GARCIA
Marc GÜELL CARGOL
Maria PALLARÈS MASMITJÀ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Integra Therapeutics
Universitat Pompeu Fabra UPF
Original Assignee
Integra Therapeutics
Universitat Pompeu Fabra UPF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integra Therapeutics, Universitat Pompeu Fabra UPF filed Critical Integra Therapeutics
Publication of EP4522735A1 publication Critical patent/EP4522735A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Definitions

  • the present invention relates to methods for improving transgene expression in a cell population.
  • NPCs nuclear pore complexes
  • Transposases are enzymes naturally evolved to “cut-and-paste” or “copy-and-paste” DNA fragments into genomic DNA of prokaryotes (e.g., Tn3, Tn5 and Tn7) or eukaryotes (e.g., Sleeping Beauty, and PiggyBac). These enzymes have been found in the genome of certain species with low transposition efficiencies to avoid genomic toxicity. Transposases bind to a payload DNA containing specific Inverted Terminal Repeats (ITRs) called transposon, copy or cut its sequence pasting it in a random or semi-random genomic site.
  • ITRs Inverted Terminal Repeats
  • transposases are naturally addressed to the nucleus thanks to a nuclear localization signal (see, e.g., Keith et al. “Analysis of the piggyBac transposase reveals a functional nuclear targeting signal in the 94 c-terminal residues.” BMC Molecular Biology 2008, vol. 9, 72).
  • the state of the art comprises different transposases that were modified to increase their efficiency and to create tools for mammalian genome editing such as SB 100 or hyperactive PiggyBac.
  • Transposases have also been fused to DNA binding domains such as, e.g., Cas9 (see, e.g., WO2022129438 or W02020243085), dead-Cas9 (see, e.g., Hew et al. “RNA-guided piggyBac transposition in human cells.” Synthetic Biology 2019, vol. 4,1), and ZNF, in order to specifically target and edit a certain genomic DNA location.
  • Cas9 see, e.g., WO2022129438 or W02020243085
  • dead-Cas9 see, e.g., Hew et al. “RNA-guided piggyBac transposition in human cells.” Synthetic Biology 2019, vol. 4,1)
  • ZNF in order to specifically target and edit a certain genomic DNA location.
  • transposases have been described as tools for genome editing (see, e.g., Zhao et al. “PiggyBac transposon vectors: the tools of the human gene encoding.” Translational Lung Cancer Research 2016, vol. 5,1)
  • their applications rely on their insertional activity, either for inserting a gene in a host cell’s DNA, or for disrupting a gene, which also poses the problem of insertional mutagenesis.
  • transfection is usually performed on actively dividing (proliferating) cells, because they internalize nucleic acids much better than non-dividing, quiescent cells (Bai et al. 2017), and it is notably difficult to transfect confluent cells or certain cell types that do not divide in culture. Hence, there is a need to improve transfection efficiency in non-dividing cells.
  • the present invention provides evidence that, using transposases with vehicles that facilitates cytoplasmatic transduction of nucleic acids, it is possible to increase the nuclear localization or nuclear uptake of a DNA of interest, where it can then be expressed by the cell (z.e., transiently expressed, transfected) or inserted in the genomic DNA.
  • the method of the present invention also enables efficient transfection of quiescent cells.
  • the method of the present invention also enables efficient transfection without insertional activity when using a catalytically inactive transposase.
  • An object of the present invention is a method of increasing the expression of a nucleic acid molecule encoding at least one transgene of interest in a cell population, comprising contacting a cell population with: a protein or polypeptide comprising a transposase or a fragment thereof, or a nucleic acid encoding the same, and the nucleic acid molecule encoding the at least one transgene of interest.
  • Another object of the present invention is a method of increasing nuclear localization of a nucleic acid molecule encoding at least one transgene of interest in a cell population, comprising contacting a cell population with: a protein or polypeptide comprising a transposase or a fragment thereof, or a nucleic acid encoding the same, and the nucleic acid molecule encoding the at least one transgene of interest.
  • Another object of the present invention is a method of editing the genome of a cell population, comprising contacting a cell population with: a protein or polypeptide comprising a transposase or a fragment thereof, or a nucleic acid encoding the same, and the nucleic acid molecule encoding the at least one transgene of interest.
  • Another object of the present invention is a method of treating a genetic disease in a subject in need thereof, comprising administering said subject with a therapeutically effective amount of: a protein or polypeptide comprising a transposase or a fragment thereof, or a nucleic acid encoding the same, and a nucleic acid molecule encoding the at least one transgene of interest, wherein expression of the transgene of interest in at least one cell of the subject in need thereof compensates a gene defect responsible for the genetic disease.
  • the nucleic acid molecule encoding the at least one transgene of interest is a deoxyribonucleic acid (DNA) molecule.
  • said DNA molecule is a complementary DNA (cDNA) molecule.
  • said DNA molecule is a genomic DNA (gDNA) molecule.
  • the nucleic acid molecule encoding the at least one transgene of interest further comprises at least one Inverted Terminal Repeat (ITR) sequence.
  • ITR Inverted Terminal Repeat
  • the nucleic acid molecule encoding the at least one transgene of interest further comprises two ITR sequences.
  • the at least one ITR sequence is adjacent to the transgene of interest.
  • the nucleic acid molecule encoding the at least one transgene of interest further comprises two ITR sequences flanking the transgene of interest.
  • the at least one ITR sequence interacts with, or non-covalently binds to, the transposase.
  • the DNA molecule is inserted into the genome of said cell population.
  • the nucleic acid molecule encoding the at least one transgene of interest is stably expressed by the cell population.
  • the transgene of interest is an exogenous gene. In some embodiments, the transgene of interest is an endogenous gene.
  • the nucleic acid molecule encoding the at least one transgene of interest is comprised in a plasmid, a fosmid, a cosmid, an artificial chromosome or a viral vector. In some embodiments, the nucleic acid molecule encoding the at least one transgene of interest is comprised in a plasmid. In some embodiments, the nucleic acid molecule encoding the at least one transgene of interest is comprised in a viral vector.
  • the nucleic acid molecule encoding the at least one transgene of interest is comprised in a DNA virus-based vector selected from the group consisting of viruses from the realms Duplodnaviria, Monodnaviria and Varidnaviria.
  • the protein or polypeptide comprising the transposase or a fragment thereof increases the nuclear localization of the nucleic acid molecule encoding the at least one transgene of interest. In some embodiments, the protein or polypeptide comprising the transposase or a fragment thereof translocates, or promotes translocation of, the nucleic acid molecule encoding the at least one transgene of interest to the nucleus.
  • the protein or polypeptide comprising the transposase or a fragment thereof is a fusion protein comprising the transposase or a fragment thereof, and at least one additional polypeptide or protein.
  • the at least one additional polypeptide or protein is a nuclease.
  • the at least one additional polypeptide or protein is a RNA-guided nuclease.
  • the at least one additional polypeptide or protein is a Cas nuclease.
  • the at least one additional polypeptide or protein is a Cas9 nuclease.
  • the fusion protein further comprises a linker.
  • the fusion protein has at least 75 % amino acid sequence identity with SEQ ID NO: 2. In some embodiments, the fusion protein comprises or consists of the amino acid sequence of SEQ ID NO: 2.
  • the at least one additional polypeptide or protein is an aptamer binding protein.
  • the at least one additional polypeptide or protein is the MS2 bacteriophage coat protein (MCP).
  • MCP MS2 bacteriophage coat protein
  • the fusion protein interacts, or is capable of interacting, covalently or non-covalently through MCP with a gRNA molecule comprising at least one MS2 aptamer.
  • the gRNA molecule interacts, or is capable of interacting, covalently or non-covalently through the at least one MS2 aptamer with an RNA-guided nuclease.
  • the transposase is selected from the group consisting of hyperactive PiggyBac transposase, PiggyBac transposase, Sleeping Beauty transposase, SB 11 transposase, Tol2 transposase, Mosl transposase, and Frog Prince transposase.
  • the transposase is selected from the group consisting of hyperactive PiggyBac transposase and Sleeping Beauty transposase.
  • the transposase is a hyperactive PiggyBac transposase.
  • the transposase is a hyperactive PiggyBac transposase with the amino acid sequence of SEQ ID NO: 1.
  • the transposase is a modified hyperactive PiggyBac transposase, comprising at least one amino acid mutation compared with the amino acid sequence of the hyperactive PiggyBac transposase of SEQ ID NO: 1.
  • the transposase is a Sleeping Beauty transposase.
  • the transposase or the fragment thereof has decreased catalytic activity.
  • the transposase or the fragment thereof is catalytically dead.
  • the catalytically dead transposase has at least 75 % amino acid sequence identity with SEQ ID NO: 3. In some embodiments, the catalytically dead transposase comprises or consists of the amino acid sequence of SEQ ID NO: 3.
  • the protein or polypeptide comprises a transposase fragment.
  • the transposase fragment comprises or consists of at least one transposase functional domain.
  • the transposase fragment comprises or consists of an ITR-binding domain.
  • the transposase fragment is a fragment of a hyperactive PiggyBac transposase or of a Sleeping Beauty transposase.
  • the transposase fragment is a fragment of a hyperactive PiggyBac transposase, preferably comprising an ITR-binding domain.
  • the transposase fragment is a fragment of a Sleeping Beauty transposase, preferably selected from the group consisting of the SB 100 domain and the N57 domain of Sleeping Beauty transposase.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is a ribonucleic acid (RNA) molecule or a DNA molecule. In some embodiments, the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is an RNA molecule. In some embodiments, the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is a messenger RNA (mRNA) molecule.
  • mRNA messenger RNA
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is a cDNA molecule or a plasmid. In some embodiments, the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population by transfection or transformation. In some embodiments, transfection is selected from the group consisting of lipofection, electroporation, sonication, nanoparticles, microinjection and viral vector infection, including non-integrative and integrative viral vector infection. In some embodiments, transformation comprises using an integrative viral vector or a modified integrative virus.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population together with the nucleic acid molecule encoding the at least one transgene of interest. In some embodiments, the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population prior to the nucleic acid molecule encoding the at least one transgene of interest. In some embodiments, the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population from 1 hour to 72 hours before the nucleic acid molecule encoding the at least one transgene of interest. In some embodiments, the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population about 4 hours before the nucleic acid molecule encoding the at least one transgene of interest.
  • the protein or polypeptide comprising a transposase or a fragment thereof, or the nucleic acid encoding the same is comprised in a pharmaceutical composition further comprising at least one acceptable excipient.
  • the cell population is a eukaryotic or a prokaryotic cell population. In some embodiments, the cell population is a eukaryotic cell population. In some embodiments, the cell population is a prokaryotic cell population. In some embodiments, the method is performed in vitro. In some embodiments, the cell population is an in vztro-cultured population of cells. In some embodiments, the method is performed ex vivo. In some embodiments, the method is performed in vivo.
  • the cell population is comprised in a tissue or an organ of a living organism.
  • the organism is an animal.
  • the organism is a mammal.
  • the organism is a human.
  • the method comprises the steps of: contacting the cell population with a vector comprising the nucleic acid encoding the protein or polypeptide comprising the transposase or a fragment thereof, culturing the cell population for a period of time ranging from 1 hour to 72 hours, and contacting the cell population with a vector comprising the nucleic acid molecule encoding the at least one transgene of interest.
  • the method comprises the steps of: contacting the cell population with a vector comprising the protein or polypeptide comprising the transposase or a fragment thereof, and contacting the cell population with a vector comprising the nucleic acid molecule encoding the at least one transgene of interest.
  • Cas9 or“ Cas9 nuclease” refer to an RNA-guided nuclease comprising a Cas9 protein, or a fragment thereof (e.g., a protein comprising an active or inactive DNA cleavage domain of Cas9, and/or the gRNA binding domain of Cas9).
  • a Cas9 nuclease is also referred to sometimes as a casnl nuclease or a CRISPR (clustered regularly interspaced short palindromic repeat)-associated nuclease.
  • CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids).
  • CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems, correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and a Cas9 protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently, the Cas9/crRNA/tracrRNA complex endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer.
  • tracrRNA trans-encoded small RNA
  • rnc endogenous ribonuclease 3
  • Cas9 protein The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA.
  • the target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3 ‘-5’ exonucleolytically.
  • DNA-binding and cleavage typically requires protein and both RNAs.
  • single guide RNAs (“sgRNA” or simply “gRNA”) can be engineered so as to incorporate aspects of both the crRNA and tracrRNA into a single RNA species.
  • Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self vs. non-self.
  • Cas9 nuclease sequences and structures are well known to those of skill in the art. Cas9 orthologs have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus.
  • Exogenous refers to any molecule that is not naturally present in a cell or organism of interest, but which can be introduced thereinto by one or more genetic, biochemical or other methods.
  • the natural presence of a molecule in a cell or organism may also be determined with respect to the particular developmental stage and environmental conditions thereof.
  • a molecule that is present only during embryonic development of muscle is an exogenous molecule with respect to an adult muscle cell.
  • a molecule induced by heat shock is an exogenous molecule with respect to a non-heat-shocked cell.
  • exogenous molecule can comprise, e.g., a functioning version of a malfunctioning endogenous molecule or a malfunctioning version of a normally functioning endogenous molecule.
  • endogenous coins any molecule that is normally present in a cell or organism, at a particular developmental stage under particular environmental conditions.
  • Fusion protein refers to a single-chain hybrid polypeptide which comprises two or more amino acid sequences fused together (z.e., from two or more different proteins and/or peptides). The two or more amino acid sequences can be fused together via a direct peptidic bond or indirectly through a peptidic linker. A fusion protein may be in particular fully encoded by a single nucleic acid sequence.
  • Gene typically refers to a DNA region encoding a protein (z.e., a coding region).
  • the term may also include DNA regions which do not per se encode a protein (z.e., a non-coding region).
  • the latter include, e.g., regions transcribed into functional non-coding RNA molecules (e.g., transfer RNA, ribosomal RNA, regulatory RNA, etc.).
  • Other non-coding regions regulate the transcription and translation of coding regions (z. e. , regulatory elements), or serve as architectural elements (e.g., scaffold/matrix attachment region), as origins of DNA replication, as centromeres or telomeres, etc.
  • Regulatory elements include, without limitations, promoter sequences, terminators, translational regulatory sequences (e.g., ribosome binding sites [RBS] and internal ribosome entry sites [IRES]), enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions.
  • translational regulatory sequences e.g., ribosome binding sites [RBS] and internal ribosome entry sites [IRES]
  • enhancers e.g., ribosome binding sites [RBS] and internal ribosome entry sites [IRES]
  • enhancers e.g., ribosome binding sites [RBS] and internal ribosome entry sites [IRES]
  • enhancers e.g., ribosome binding sites [RBS] and internal ribosome entry sites [IRES]
  • enhancers e.g., ribosome binding sites [RBS] and internal ribosome entry sites [IRES]
  • enhancers e.g
  • Identity when used in a relationship between the sequences of two or more amino acid sequences, or of two or more nucleic acid sequences, refers to the degree of sequence relatedness between amino acid sequences or nucleic acid sequences, as determined by the number of matches between strings of two or more amino acid residues or nucleic acid residues. “Identity” measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (z.e., “algorithms”). Identity of related amino acid sequences or nucleic acid sequences can be readily calculated by known methods. Such methods include, but are not limited to, those described in Lesk A. M. (1988).
  • Preferred methods for determining identity are designed to give the largest match between the sequences tested. Methods of determining identity are described in publicly available computer programs. Preferred computer program methods for determining identity between two sequences include the GCG program package, including GAP (Genetics Computer Group, University of Wisconsin, Madison, WI; Devereux et al., 1984. Nucleic Acids Res . 12(1 Pt l):387-95), BLASTP, BLASTN, and FASTA (Altschul etal., 1990. J Mol Biol. 215(3):403-10). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al. NCB/NLM/NIH Bethesda, Md. 20894). The well-known Smith Waterman algorithm may also be used to determine identity.
  • GAP Genetics Computer Group, University of Wisconsin, Madison, WI; Devereux et al., 1984. Nucleic Acids Res . 12(1 P
  • Insertion refers to the addition of a nucleic acid sequence into a second nucleic acid sequence or into a genome or a portion thereof. Insertion may be “specific”, “site-specific”, “targeted” or “on-targeted”: these adjectives define the insertion of a nucleic acid into a specific site of a second nucleic acid or into a specific site of a genome or a portion thereof (i.e., a site that has been purposely selected for insertion). Conversely, the adjectives “random”, “non-targeted” or “off-targeted” refer to non-specific and/or unintended insertion of a nucleic acid into an unwanted site. The terms “total” or “overall” refer to the total number of insertions.
  • Linker refers to a chemical group or a molecule linking two adjacent molecules or moieties.
  • Modified refers to a protein or nucleic acid sequence that is different than a corresponding unmodified protein or nucleic acid sequence.
  • “Mutated”, in connection with a sequence means that the sequence is different than a reference sequence, such as a wild-type sequence.
  • a mutated sequence comprises at least one of a substitution, an addition or a deletion of one or several residues by comparison to a reference sequence, such as a corresponding wild-type sequence.
  • “Mutation” refers to a substitution of a residue within a sequence, e.g., a nucleic acid or amino acid sequence, with another residue; and/or to a deletion or insertion of one or more residues within a nucleic acid or amino acid sequence. Mutations are typically described herein by identifying the original residue followed by the position of the residue within the sequence, then the identity of the newly substituted residue. Various methods for making amino acid substitutions (mutations) provided herein are well known in the art, and are provided by, for example, Green & Sambrook, 2012 (Molecular cloning: a laboratory manual (4 th Ed.). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).
  • Nuclease refers to an enzyme catalyzing the hydrolysis of nucleic acids within a nucleic acid sequence. Nuclease activity can result in single-stranded or double-stranded nucleic acid molecules break, wherein the nucleic molecule can be DNA or RNA.
  • Nucleic acid molecule/sequence
  • nucleotide sequence may be used interchangeably to refer to any molecule composed of, or comprising, monomeric nucleotides.
  • a nucleic acid may be an oligonucleotide or a polynucleotide; it can be a DNA, an RNA, or a mix thereof. It can be chemically modified or artificial; e.g., it encompasses peptide nucleic acids (PNA), morpholinos and locked nucleic acids (LNA), as well as glycol nucleic acids (GNA) and threose nucleic acid (TNA).
  • PNA peptide nucleic acids
  • LNA locked nucleic acids
  • GAA glycol nucleic acids
  • TAA threose nucleic acid
  • nucleic acids distinguish from naturally occurring DNA or RNA by changes in the backbone of the molecule.
  • phosphorothioate nucleotides may be used.
  • Other deoxynucleotide analogs include, without limitation, methylphosphonates, phosphoramidates, phosphorodithioates, N3'P5' phosphoramidates and oligoribonucleotide phosphorothioates and their 2’O-allyl analogs and 2’O-methylribonucleotide methylphosphonates which may be used in a nucleic acid of the disclosure.
  • Polypeptide”, “peptide”, “protein” and “amino acid sequence” are used interchangeably to refer to a polymer of amino acid residues. Unless specified, a polymer of amino acid residues can be any length. The term also applies to amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of corresponding naturally-occurring amino acids.
  • Prevention and any declension thereof refers to prophylactic and preventative measures, wherein the object is to reduce the chances that a subject will develop a given pathologic condition or disorder over a given period of time. Such a reduction may be reflected, e.g., in a delayed onset of at least one symptom of the pathologic condition or disorder in the subject.
  • Specificity refers to the ability to selectively bind a sequence which shares a degree of sequence identity to a selected sequence.
  • Subject refers to a mammal, preferably a human.
  • a subject may be a “patient”, ie., a warm-blooded animal, more preferably a human, who/which is awaiting the receipt of, or is receiving medical care or was/is/will be the object of a medical procedure, or is monitored for the development of a disease.
  • the term “mammal” refers here to any mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc.
  • the mammal is a primate, more preferably a human.
  • Transduction and any declension thereof refers to the introduction of one or more nucleic acid molecules (DNA and/or RNA) into one or more cells using a viral vector carrier, e.g., a virus, a viral particle or a viral vector, including without limitation, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses (AAV), and vectors derived thereof.
  • a viral vector carrier e.g., a virus, a viral particle or a viral vector, including without limitation, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses (AAV), and vectors derived thereof.
  • retroviruses including lentiviruses
  • AAV adeno-associated viruses
  • Transfection and any declension thereof refers to the introduction of one or several nucleic acid molecules (DNA and/or RNA) into one or more cells by non-viral means, whether in vitro or in vivo.
  • transfection refers to any method, technique or vehicle known in the art that facilitates or increases cytoplasmic transduction of a nucleic acid molecule or cargo. Methods for transfection are well known in the art and include, e.g., lipofection, PEI and electroporation.
  • Transgene refers to an exogenous nucleic acid sequence, in particular an exogenous DNA or cDNA encoding a gene product.
  • the gene product may be an RNA, peptide or protein.
  • the transgene may include or be associated with one or more operational sequences to facilitate or enhance expression, such as a promoter, enhancer(s), response element(s), reporter element(s), insulator element(s), polyadenylation signal(s) and/or other functional elements.
  • Embodiments of the disclosure may utilize any known suitable promoter, enhancer(s), response element(s), reporter element(s), insulator element(s), polyadenylation signal(s) and/or other functional elements, unless specified otherwise. Suitable elements and sequences will be well known to those skilled in the art.
  • Transposase refers to an enzyme that binds to the end of a transposon and catalyzes its movement to another part of the genome by a cut-and-paste mechanism, or a replicative transposition mechanism.
  • the transposase may be a fragment of a transposase, e.g., an ITR-binding domain or a functional domain, preferably an ITR-binding domain.
  • “Treatment”, “alleviation”, “curation” and any declensions thereof refer to a therapeutic treatment, excluding prophylactic or preventative measures; wherein the object is to slow down, lessen, stop or even reverse (either partially or totally) the evolution of a targeted pathologic condition or disorder.
  • Those in need of treatment include those already with the disorder as well those suspected to have the disorder.
  • a subject is successfully “treated” for the targeted pathologic condition or disorder if, after receiving treatment, they show observable and/or measurable reduction in or absence of one or more symptoms associated with the pathologic condition or disorder; relief to some extent; reduced morbidity and/or mortality; and/or improvement in quality-of-life issues.
  • the above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician.
  • Vector refers to any polynucleotide that can carry, e.g., a second polynucleotide of interest, and e.g., which can transfer gene sequences to target cells.
  • the term includes cloning, and expression vehicles, as well as integrating vectors.
  • the present invention thus relates to a method of increasing the expression of a nucleic acid molecule encoding at least one transgene of interest in a cell population.
  • It also relates to a method of increasing nuclear localization of a nucleic acid molecule encoding at least one transgene of interest in a cell population.
  • It also relates to a method of editing the genome of a cell population, in particular by inserting a nucleic acid molecule encoding at least one transgene of interest in the genome of the cell population.
  • It also relates to a method of transfecting a nucleic acid molecule encoding at least one transgene of interest in a cell population, preferably a non-dividing cell population.
  • the nucleic acid molecule encoding the at least one transgene of interest is transfected in the cell population by at least one technique selected from the group comprising or consisting of lipofection, electroporation, sonication, nanoparticles, microinjection, PEI, and viral vector infection, including non-integrative and integrative viral vector infection.
  • the invention is based on the observation by the Inventors that a cytoplasmic transposase was capable of delivering a nucleic acid to the nucleus of a cell, thereby increasing its nuclear localization.
  • a cytoplasmic transposase is capable of translocating, or of promoting translocation, of a nucleic acid to the nucleus of a cell, including a quiescent cell. Increased nuclear localization thus induces increased expression levels of the nucleic acid.
  • the Inventors observed that increased nuclear localization by the transposase does not rely on its enzymatic activity.
  • a DNA molecule encoding the at least one transgene of interest when delivered to the cytoplasm of a cell, will be sensed by the immune system of the cell that will induce a response against the presence of a foreign DNA (e.g., inflammatory response). Besides, the DNA molecule encoding the at least one transgene of interest will also have to pass the nuclear envelope in order to reach the nucleus. These problems are overcome when the DNA molecule encoding the at least one transgene of interest is translocated by a cytoplasmic transposase.
  • these methods comprise contacting a cell population with: the nucleic acid molecule encoding the at least one transgene of interest, and a protein or polypeptide comprising a transposase or a fragment thereof, or a nucleic acid encoding the same.
  • the nucleic acid molecule encoding the at least one transgene of interest is delivered to the cell population by transfection.
  • the nucleic acid molecule encoding the at least one transgene of interest is transfected in the cell population by at least one technique selected from the group comprising or consisting of lipofection, electroporation, sonication, nanoparticles, microinjection, PEI, and viral vector infection, including non-integrative and integrative viral vector infection.
  • the cell population may be contacted with the nucleic acid molecule encoding the at least one transgene of interest, and the protein or polypeptide comprising a transposase or a fragment thereof or a nucleic acid encoding the same, in any order.
  • the cell population is contacted with the nucleic acid molecule encoding the at least one transgene of interest concomitantly with the protein or polypeptide comprising a transposase or a fragment thereof or a nucleic acid encoding the same.
  • the cell population is contacted with the protein or polypeptide comprising a transposase or a fragment thereof or a nucleic acid encoding the same prior to being contacted with the nucleic acid molecule encoding the at least one transgene of interest.
  • the cell population is contacted with the nucleic acid molecule encoding the at least one transgene of interest prior to being contacted with the protein or polypeptide comprising a transposase or a fragment thereof or a nucleic acid encoding the same.
  • nucleic acid molecule encoding the at least one transgene of interest refers to a nucleic acid sequence to be inserted in the genome of a cell, preferably of a eukaryotic cell, more preferably of a mammalian cell (including of a human cell), that encodes at least one product of interest.
  • the product of interest may be a protein or a fragment thereof; in this case, the transgene of interest is said to be a coding nucleic acid sequence.
  • RNA gene or “non-coding RNA”
  • non-coding RNA such as, e.g., a transfer RNA, a ribosomal RNA, a small RNA, a long non-coding RNA, etc.
  • the transgene of interest is a nucleic acid sequence encoding a peptide or protein (e.g., without limitation, an enzyme, a transcription factor, a growth factor, a trophic factor, a hormone, a cytokine, an antibody, an antigen, a receptor, an immune regulator, a differentiation factor, a suicide protein, a cell-cycle modifying protein, an anti-proliferative protein, an angiogenic factor, an anti-angiogenic factor, a genome editor, a nuclease, a recombinase, a transposase, a neurotransmitter, and a reporter, including any precursor thereof, as well as fusion proteins).
  • the sequence of interest may typically be (or be derived from) an mRNA, a cDNA, a gDNA, a synthetic nucleic acid, or any combinations thereof.
  • the transgene of interest is alternatively a nucleic acid sequence of a non-coding RNA.
  • RNAs examples include, but are not limited to, transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), SmY RNAs, small Cajal body-specific RNAs (scaRNAs), guide RNAs (gRNAs), Y RNAs, telomerase RNA component (TERC), spliced leader RNAs (SL RNAs), catalytic RNAs (z.e., ribozymes; such as, e.g., ribonuclease P, ribonuclease MRP, and the like), antisense RNAs (aRNAs), c/.s-natural antisense transcript (cis-NAT), CRISPR RNAs (crRNAs), long non-coding RNAs (IncRNAs), microRNAs (miRNAs), piwi-interacting RNAs (p
  • transgene of interest examples include any nucleic acid sequence encoding a molecule of therapeutic interest, such as any nucleic acid sequence encoding a peptide or protein, or a non-coding RNA, that is lacking, deficient and/or non-functional in a subject.
  • the nucleic acid molecule encoding the at least one transgene of interest comprises the at least one transgene and at least one regulatory element.
  • regulatory elements include, without limitation, promoters, enhancers, silencers, insulators and the like.
  • the at least one regulatory element is located upstream, i.e., in 5’, of the at least one transgene of interest.
  • the nucleic acid molecule encoding the at least one transgene of interest may be double-stranded or single-stranded.
  • the nucleic acid molecule encoding the at least one transgene of interest may be a deoxyribonucleic acid (DNA) molecule, a ribonucleic acid (RNA) molecule, or a mix thereof; preferably nucleic acid molecule encoding the at least one transgene of interest is a DNA molecule.
  • the nucleic acid molecule encoding the at least one transgene of interest typically comprises natural nucleotides. It may however also comprise non-natural nucleotides.
  • a “natural nucleotide” refers to adenine (A), guanine (G), cytosine (C), thymine (T) and uracil (U).
  • non-natural nucleotides refers to chemically modified A, T, U, C or G nucleotides.
  • the nucleic acid molecule encoding the at least one transgene of interest has a length of at least 10 base pairs (bp), such as at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1 000, 2 000, 3 000, 4 000, 5 000, 6 000, 7 000, 8 000, 9 000, 10 000, 20 000, 30 000, 40 000, 50 000, 60 000, 70 000, 80 000, 90 000, 100 000 bp or more.
  • bp base pairs
  • the nucleic acid molecule encoding the at least one transgene of interest is a DNA molecule selected from the group comprising or consisting of a complementary DNA (cDNA) and a genomic DNA (gDNA).
  • cDNA complementary DNA
  • gDNA genomic DNA
  • the DNA molecule is a cDNA.
  • the DNA molecule is a gDNA.
  • the nucleic acid molecule encoding the at least one transgene of interest further comprises at least one Inverted Terminal Repeat (ITR) sequence.
  • ITR Inverted Terminal Repeat
  • an “ITR sequence” refers to a nucleic acid sequence naturally found at the extremities of eukaryotic transposable elements (or transposons). They are referred to as “5’ ITR” and “3’ ITR”. Typically, the 5’ ITR and the 3’ ITR are complementary and capable of forming a hairpin structure. ITR sequences are useful for the recognition of the transposon by a transposase enzyme. In some embodiments, the ITR sequences are palindromic.
  • ITR sequences include SEQ ID NOs: 55 to 60, as well as complementary sequences thereof.
  • SEQ ID NO: 56 ccctagaaagatagtctgcgtaaaattgacgcatgagataatcaatattgtgacgtacgttaa
  • SEQ ID NO: 60 catgcgtcaattttacgcatgattatctttaacgtacgtacgtcacaatatgattatctttctaggg
  • the at least one ITR sequence interacts with, or non-covalently binds to, the protein or polypeptide comprising a transposase or a fragment thereof.
  • the protein or polypeptide comprising a transposase or a fragment thereof specifically recognizes and binds to the at least one ITR sequence.
  • the at least one ITR sequence is adjacent to the transgene of interest.
  • adjacent it is meant that no nucleotide separates the transgene of interest from the at least one ITR sequence.
  • the at least one ITR sequence can be separated from the transgene of interest by at least one nucleotide, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 nucleotides or more.
  • the nucleic acid molecule encoding the at least one transgene of interest comprises two ITR sequences.
  • the two ITR sequences flank the transgene of interest.
  • the two ITR sequences are directly flanking the transgene of interest, z.e., no nucleotide separates the transgene of interest from the two flanking ITR sequences.
  • the transgene of interest can be separated from at least one of the two ITR sequences, or from both ITR sequences, by at least one nucleotide, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 nucleotides or more.
  • the nucleic acid molecule encoding the at least one transgene of interest is either stably or transiently expressed by the cell population, preferably stably expressed.
  • the nucleic acid molecule encoding the at least one transgene of interest is transiently expressed.
  • the nucleic acid molecule encoding the at least one transgene of interest is transfected.
  • the transfection comprises the use of at least one vehicle and/or method that facilitates or increases cytoplasmic transduction of the nucleic acid molecule encoding at least one transgene of interest. Examples of transfection techniques include, without limitation, lipofection, electroporation, sonication, nanoparticles, microinjection, PEI, and viral vector infection, including non-integrative and integrative viral vector infection.
  • the nucleic acid molecule encoding the at least one transgene of interest is a DNA molecule which is inserted into the genome of the cells of the cell population. It is to be understood that the term “inserted in the genome” implies that the DNA molecule is replicated alongside the genome of the cell during mitosis.
  • the transgene of interest may be an exogenous gene or an endogenous gene.
  • the transgene of interest is an exogenous gene.
  • exogenous gene refers to a gene that is not naturally present in a cell, but can be introduced into the cell by one or more genetic, biochemical or other methods. Natural presence in the cell may be determined with respect to the particular developmental stage and environmental conditions of the cell. For instance, a molecule that is present only in a cell during embryonic development is exogenous with respect to an adult stage cell. Similarly, a molecule induced by heat-shocking a cell is exogenous with respect to a non-heat- shocked cell.
  • the transgene of interest is an endogenous gene.
  • endogenous gene refers to a gene of which at least one copy is naturally present in the genome of the population of cells.
  • the at least one copy may be an allele, z.e., a version of the gene comprising at least one mutation.
  • expression of a transgenic endogenous gene increases the overall expression levels (z.e., transcripts) of the gene.
  • the nucleic acid molecule encoding the at least one transgene of interest is comprised in a vector, such as, without limitation, a plasmid, a fosmid, a cosmid, an artificial chromosome or a viral vector.
  • the nucleic acid molecule encoding the at least one transgene of interest is comprised in a plasmid.
  • the plasmid may be circular or linear, preferably circular.
  • the nucleic acid molecule encoding the at least one transgene of interest is comprised in a fosmid.
  • the nucleic acid molecule encoding the at least one transgene of interest is comprised in a cosmid.
  • the nucleic acid molecule encoding the at least one transgene of interest is comprised in an artificial chromosome (e.g., human artificial chromosome).
  • the nucleic acid molecule encoding the at least one transgene of interest is comprised in a viral vector.
  • the viral vector may be a DNA virus-based vector.
  • DNA virus-based vectors include vectors derived from viruses from the Duplodnaviria, Monodnaviria or Varidnaviria realms.
  • the DNA virus-based vector is derived from a virus from the Duplodnaviria realm. Viruses from the Duplodnaviria realm include viruses of the Herpesvirales order. In some embodiments, the DNA virus-based vector is therefore a vector derived from Herpesviridae, such as, e.g., from a herpes simplex virus.
  • the DNA virus-based vector is derived from a virus from the Monodnaviria realm. Viruses from the Monodnaviria realm include viruses of the Papillomaviridae and Polyomaviridae families. In some embodiments, the DNA virus-based vector is therefore a vector derived from a Papillomaviridae or a Polyomaviridae .
  • the DNA virus-based vector is derived from a virus from the Varidnaviria realm.
  • Viruses from the Varidnaviria realm include viruses of the Adenoviridae and Poxviridae families.
  • the DNA virus-based vector is therefore a vector derived from an Adenoviridae, such as, e.g., from an adenovirus; or derived from Poxviridae, such as, e.g., from a vaccina virus.
  • the nucleic acid molecule encoding the at least one transgene of interest can be excised from the vector. In some embodiments, the nucleic acid molecule encoding the at least one transgene of interest can be excised from the vector by the at least one ITR sequence, typically by a transposase, or variant or fragment thereof.
  • the protein or polypeptide comprising the transposase or a fragment thereof increases the nuclear localization of the nucleic acid molecule encoding the at least one transgene of interest.
  • “increases the nuclear localization” means that the nuclear localization of the nucleic acid molecule encoding the at least one transgene of interest is increased at least 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold or more in presence of the protein or polypeptide comprising the transposase or a fragment thereof, compared to a condition in absence of the protein or polypeptide comprising the transposase or
  • the protein or polypeptide comprising the transposase or a fragment thereof translocates, or promotes translocation of, the nucleic acid molecule encoding the at least one transgene of interest to the nucleus.
  • the transposase or a fragment thereof (i) interacts and/or non-covalently binds with the nucleic acid molecule encoding the at least one transgene of interest, and (ii) translocates to the nucleus.
  • the transposase or a fragment thereof does not insert and/or transpose the nucleic acid molecule encoding the at least one transgene of interest into the genome.
  • the transposase or a fragment thereof increases at least 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold or more, the passage of the nucleic acid molecule encoding the at least one transgene of interest through the nuclear envelope.
  • the transposase or a fragment thereof protects the nucleic acid molecule encoding the at least one transgene of interest from the cell’s sensing mechanisms and/or defense mechanisms. In some embodiments, the transposase or a fragment thereof does not induce a proinflammatory and/or inflammatory response.
  • the transposase is selected from the group consisting of hyperactive PiggyBac transposase, PiggyBac transposase, Sleeping Beauty transposase, SB11 transposase, Tol2 transposase, Mosl transposase, and Frog Prince transposase.
  • the transposase is selected from the group consisting of hyperactive PiggyBac transposase and Sleeping Beauty transposase.
  • the transposase is a hyperactive PiggyBac transposase.
  • the transposase is a hyperactive PiggyBac transposase with the amino acid sequence of SEQ ID NO: 1.
  • the transposase is a modified hyperactive PiggyBac transposase.
  • modified hyperactive PiggyBac transposase it is referred to a transposase comprising one or more amino acid substitutions, typically no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, as compared to the hyperactive PiggyBac transposase with the amino acid sequence of SEQ ID NO: 1.
  • a modified hyperactive PiggyBac transposase may comprise (i) one or more amino acid substitutions to increase excision activity as compared to the hyperactive PiggyBac transposase with the amino acid sequence of SEQ ID NO: 1, and/or (ii) one or more amino acid substitutions to decrease DNA binding activity as compared to the hyperactive PiggyBac transposase with the amino acid sequence of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises an amino acid sequence at least 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, or 99 % identical to the sequence set forth in SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises one or more amino acid mutations to increase excision activity.
  • the modified hyperactive PiggyBac transposase comprises one or more amino acid mutations to increase excision activity selected among the amino acid mutations within the regions defined by the amino acid position numbers [194-200], [214-222], [434-442] or [446-456]; for example, amino acid substitution at the position DI 98, D201, R202, M212 and/or S213; said position number corresponding to the amino acid number of the hyperactive PiggyBac with SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises one or more amino acid mutations to increase excision activity selected among the amino acid mutations at positions 450, 560, 564, 573, 589, 592, and/or 594; said position number corresponding to the amino acid number of the hyperactive PiggyBac with SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises one or more amino acid mutations to increase excision activity selected among the amino acid mutations at position of M194 and/or D450, said position number corresponding to the amino acid number of the hyperactive PiggyBac with SEQ ID NO: 1; preferably the amino acid substitution is M194V and/or D450N.
  • the modified hyperactive PiggyBac transposase comprises one or more amino acid mutations to decrease DNA binding activity.
  • the modified hyperactive PiggyBac transposase comprises one or more amino acid mutations to decrease DNA binding activity selected among the amino acid mutations at positions 254, 275, 277, 347, 372, 375, and/or 465; said position number corresponding to the amino acid number of the hyperactive PiggyBac with SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises one or more amino acid mutations to decrease DNA binding activity selected among R275, N347, R372, K375, R376, E377, and E380, said position number corresponding to the amino acid number of the hyperactive PiggyBac with SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises one or more amino acid mutations to decrease DNA binding activity selected among R372, K375, R376, E377, and E380, said position number corresponding to the amino acid number of the hyperactive PiggyBac with SEQ ID NO: 1; preferably the amino acid substitution is R372A, K375A, R376A, E377A, and/or E380A.
  • the modified hyperactive PiggyBac transposase comprises one or more amino acid mutations to decrease DNA binding activity selected among N347, R372, and K375, said position number corresponding to the amino acid number of the hyperactive PiggyBac with SEQ ID NO: 1; preferably the amino acid substitution is N347S, N347A, R372A, and/or K375A; more preferably the amino acid substitution is N347S or N347A.
  • the modified hyperactive PiggyBac transposase comprises one or more amino acid mutations to increase excision activity, as defined above; and one or more amino acid mutations to decrease DNA binding activity, as defined above.
  • the modified hyperactive PiggyBac transposase includes at least one amino acid substitution to increase excision activity at position D450, and at least two amino acid substitutions to decrease DNA binding activity at positions N347, R372 and K375; preferably said modified transposase of hyperactive PiggyBac comprises the double mutations N347S and D450N or triple mutations D450N, R372A and K375A, said position number corresponding to the amino acid number of the hyperactive PiggyBac with SEQ ID NO: 1.
  • the modified transposase of hyperactive PiggyBac comprises the double mutations N347S and D450N, said position number corresponding to the amino acid number of the hyperactive PiggyBac with SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase as disclosed in the previous embodiments further comprises at least one mutation in the region defined by the amino acid position numbers [158-169], for example A166S; and/or at least one mutation at position Y527, R518, K525, N463.
  • the modified hyperactive PiggyBac transposase further comprises one or more amino acid substitution at positions 34, 43, 117, 202, 230, 245, 268, 275, 277, 287, 290, 315, 325, 341, 346, 347, 350, 351, 356, 357, 388, 409, 411, 412, 432, 447, 460, 461, 465, 517, 560, 564, 571, 573, 576, 586, 587, 589, 592, and/or 594, the position number corresponding to the amino acid number of the hyperactive PiggyBac with SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises one of the following amino acid substitution or combination of amino acid substitutions: V34M, T43I, Y177H, R202K, S230N, R245A, D268N, K287A, K290A, K287A/K290A, R315A, G325A, R341A, D346N, N347A, N347S, T350A, S351E, S351P, S351A, K356E, N357A, R388A, K409A, A411T, K412A, K432A, D447A, D447N, D450N, R460A, K461A, W465A, S517A, T560A, S564P, S571N, S573A, K576A, H586A, I587A, M589V, S592G, F594L,
  • the modified hyperactive PiggyBac transposase comprises one of the following amino acid substitution or combination of amino acid substitutions:
  • modified hyperactive PiggyBac transposases include modified hyperactive PiggyBac comprising one of the following combinations of amino acid substitutions:
  • R275A/325A/R372A/T560A the position number corresponding to the amino acid number of the hyperactive PiggyBac with SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises one of the following combinations of amino acid substitutions:
  • the modified hyperactive PiggyBac transposase comprises one of the following combinations of amino acid substitutions: N347A/D450N,
  • R275A/R277A/N347S/R372A/D450N/T560A/S564P/F594L R245A/N347S/R372A/D450N/T560A/S564P/S573A/S592G, R277A/G325A/N347A/K375A/D450N/T560A/S564P/S573A/S592G/F594L, G325A/N347S/K375A/D450N/S573A/M589V/S592G, S230N/R277A/N347S/K375A/D450N, G325A/N347S/S351A/K375A/D450N/S573A/M589V/S592G, or Y177H/R275A/G325A/K375A/D450N/T560A/S564P/S592G
  • the modified hyperactive PiggyBac transposase comprises the R372A/K375A/D450N substitutions, said position numbers corresponding to the amino acid numbers of the hyperactive PiggyBac with SEQ ID NO: 1.
  • Said modified transposase has an amino acid sequence of SEQ ID NO: 4.
  • the modified hyperactive PiggyBac transposase has an amino acid sequence selected from the group comprising or consisting of SEQ ID NOs: 5-26.
  • the modified hyperactive PiggyBac transposase has an amino acid sequence selected from the group comprising or consisting of SEQ ID NOs: 5-13.
  • the modified hyperactive PiggyBac transposase has an amino acid sequence selected from the group comprising or consisting of SEQ ID NOs: 14-26.
  • the modified hyperactive PiggyBac transposase may comprise one or more mutations relative to hyperactive PiggyBac transposase that are involved in the conserved catalytic triad, e.g., at amino acid 268 and/or 346 (e.g., D268N and/or D346N) corresponding to the amino acid numbering of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase may comprise one or more mutations relative to hyperactive PiggyBac transposase that are critical for excision, e.g., at amino acid 287, 287/290 and/or 460/461 (e.g., K287A, K287A/K290A, and/or R460A/K461A) corresponding to the amino acid numbering of SEQ ID NO: 1.
  • 460/461 e.g., K287A, K287A/K290A, and/or R460A/K461A
  • the modified hyperactive PiggyBac transposase may comprise one or more mutations relative to hyperactive PiggyBac transposase that are involved in target joining, e.g., at amino acid 351, 356, and/or 379 (e.g., S351E, S351P, S351A, and/or K356E) corresponding to the amino acid numbering of SEQ ID NO: 1.
  • amino acid 351, 356, and/or 379 e.g., S351E, S351P, S351A, and/or K356E
  • the modified hyperactive PiggyBac transposase may comprise one or more mutations relative to hyperactive PiggyBac transposase that are critical for integration, e.g., at amino acid 560, 564, 571, 573, 589, 592, and/or 594 (e.g., T560A, S564P, S571N, S573A, M589V, S592G, and/or F594L) corresponding to the amino acid numbering of SEQ ID NO: 1.
  • amino acid 560, 564, 571, 573, 589, 592, and/or 594 e.g., T560A, S564P, S571N, S573A, M589V, S592G, and/or F594L
  • the modified hyperactive PiggyBac transposase may comprise one or more mutations relative to hyperactive PiggyBac transposase that are involved in alignment, e.g., at amino acid 325, 347, 350, 357 and/or 465 (e.g., G325A, N347A, N347S, T350A and/or W465A) corresponding to the amino acid numbering of SEQ ID NO: 1.
  • amino acid 325, 347, 350, 357 and/or 465 e.g., G325A, N347A, N347S, T350A and/or W465A
  • the modified hyperactive PiggyBac transposase may comprise one or more mutations relative to hyperactive PiggyBac transposase that are well conserved, e.g., at amino acid 576 and/or 587 (e.g., K576A and/or I587A) corresponding to the amino acid numbering of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase may comprise one or more mutations relative to hyperactive PiggyBac transposase that are involved in Zn 2+ binding, e.g., 586 (e.g., H586A) corresponding to the amino acid numbering of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase may comprise one or more mutations relative to hyperactive PiggyBac transposase that are involved in integration, e.g., 315, 341, 372, and/or 375 (e.g., R315A, R341A, R372A, and/or K375A) corresponding to the amino acid numbering of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac is selected for its high specificity of DNA integration into a genome compared to hyperactive PiggyBac.
  • the modified hyperactive PiggyBac comprises an amino acid sequence having one or more of the modifications disclosed herein relative to SEQ ID NO: 1, and retains at least 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity with any of SEQ ID NOs: 5-26.
  • the modified hyperactive PiggyBac transposase may comprise a mutation of one or more of amino acids selected from amino acid 245, 275, 277, 325, 347, 351, 372, 375, 388, 450, 465, 560, 564, 573, 589, 592, and 594, corresponding to the amino acid numbering of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase mutation may comprise one or more of the amino acid substitutions selected from R245A, R275A, R277A, R275A/R277A, G325A, N347A, N347S, S351E, S351P, S351A, R372A, K375A, R388A, D450N, W465A, T560A, S564P, S573A, M589V, S592G, and F594L corresponding to the amino acid numbering of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises an amino acid substitution D450N corresponding to the amino acid numbering of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises the amino acid substitutions R245A and D450, corresponding to the amino acid numbering of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises the amino acid substitutions R245A, G325A, and S573P, corresponding to the amino acid numbering of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises the amino acid substitutions R245A, G325A, D450 and S573P, corresponding to the amino acid numbering of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises the amino acid substitution N347S or N347A, corresponding to the amino acid numbering of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises the amino acid substitutions N347S and D450N, corresponding to the amino acid numbering of SEQ ID NO: 1.
  • the modified hyperactive PiggyBac transposase comprises the amino acid substitutions N347A and D450N, corresponding to the amino acid numbering of SEQ ID NO: 1.
  • This modified hyperactive PiggyBac transposase comprises the amino acid sequence of SEQ ID NO: 14.
  • the modified hyperactive PiggyBac transposase comprises or consists of an amino acid sequence having at least 75 %, 80 %, 85 %, 90 %,
  • SEQ ID NO: 20 SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24,
  • the modified hyperactive PiggyBac transposase comprises or consists of an amino acid sequence having at least 75 %, 80 %, 85 %, 90 %,
  • SEQ ID NO: 21 SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26.
  • the modified transposase is not a HimarlC9 mutant.
  • the transposase is a Sleeping Beauty transposase.
  • the transposase is a hyperactive Sleeping Beauty SB 100 transposase with the amino acid sequence of SEQ ID NO: 61.
  • the transposase is a modified hyperactive Sleeping Beauty SB 100 transposase, comprising at least one amino acid substitution compared with the amino acid sequence of an unmodified Sleeping Beauty transposase, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more substitutions.
  • the modified hyperactive Sleeping Beauty SB 100 transposase comprises one or more of the amino acid substitutions at a position selected from C176, H187, 1212, P247 and K248, corresponding to the amino acid numbering of SEQ ID NO: 61.
  • the modified hyperactive Sleeping Beauty SB 100 transposase comprises one or more of the amino acid substitutions selected from C176S, H187V/P, I212S, P247R/S, and K248A/C/I/L/M/N/R/S/T/V, corresponding to the amino acid numbering of SEQ ID NO: 61.
  • the transposase or the fragment thereof has decreased catalytic activity.
  • “decreased catalytic activity” means a 1.2-fold, 1.3-fold, 1.4-fold, l?5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold decrease, or more, compared to a wild-type transposase and/or to an hyperactive transposase.
  • the transposase or the fragment thereof is catalytically dead. In some embodiments, the transposase or the fragment thereof does not exert any catalytic activity. In some embodiments, catalytically dead transposases retain their ability to bind to other proteins, polypeptides and/or nucleic acid molecules.
  • the catalytically dead transposase has at least 75 %, 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 %, 99.5 %, 99.9 % or more sequence identity with the catalytically dead hyperactive PiggyBac transpose (dead hyPB) with SEQ ID NO: 3.
  • the dead hyPB comprises or consists of the amino acid sequence with SEQ ID NO: 3.
  • the protein or polypeptide comprises a transposase fragment.
  • the transposase fragment comprises or consists of at least one transposase functional domain.
  • the transposase fragment comprises or consists of an ITR-binding domain.
  • ITR-binding domains include, without limitation, SEQ ID NOs: 62 to 64, wherein SEQ ID NOs: 62 and 63 are ITR-binding domains of the hyperactive PiggyBac transposase and SEQ ID NO: 64 is an ITR-binding domain of the Sleeping Beauty transposase (also called “N57 targeting domain”).
  • the transposase fragment is a fragment of a hyperactive PiggyBac transposase or of a Sleeping Beauty transposase.
  • the transposase fragment is a fragment of a hyperactive PiggyBac transposase, preferably comprising an ITR-binding domain.
  • the transposase fragment is a fragment of a Sleeping Beauty transposase, preferably selected from the group consisting of the SB 100 domain and the N57 domain of Sleeping Beauty transposase.
  • the protein or polypeptide comprising the transposase or a fragment thereof is a fusion protein comprising the transposase or a fragment thereof, and at least one additional polypeptide or protein.
  • the protein or polypeptide comprising the transposase or a fragment thereof is a fusion protein comprising the transposase or a fragment thereof, and at least two additional polypeptides or proteins.
  • the fusion protein comprises a single, contiguous polypeptide chain.
  • the fusion protein further comprises at least one linker, in particular at least one peptide linker, between two polypeptides or proteins of the fusion protein.
  • Exemplary linkers include, without limitation, (G)n, (GS)n, (GGS)n, (GGGS)n (with SEQ ID NO: 49), (GGGGS)n (with SEQ ID NO: 50), (EAAAK) n (with SEQ ID NO: 51), XTEN linkers, and (XP) n linkers, as well as any combinations thereof, wherein n is an integer between 1 and 50.
  • the peptide linker is a glycine/serine-rich linker.
  • the peptide linker has an amino acid sequence selected from the group comprising or consisting of SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46.
  • the peptide linker is an XTEN linker comprising or consisting of SEQ ID NO: 47.
  • SEQ ID NO: 47 SGSETPGTSESATPES
  • the peptide linker comprises or consists of SEQ ID NO: 48.
  • the peptide linker comprises or consists of SEQ ID NO: 55.
  • Methods which are well-known to those skilled in the art can be used to construct expression vectors containing the coding sequence of a fusion protein along with appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Sambrook etal., 2012 (Molecular cloning: A laboratory manual (4 th ed.). Cold Spring Harbor Laboratory Press).
  • the expression vector can be part of a plasmid, virus, or may be a nucleic acid fragment.
  • the expression vector includes an expression cassette into which the polynucleotide encoding the fusion protein (z.e., the coding region) is cloned in operable association with a promoter and/or other transcription or translation control elements.
  • a “coding region” is a portion of nucleic acid which consists of codons translated into amino acids.
  • a “stop codon” (TAG, TGA, or TAA) is not translated into an amino acid, it may be considered to be part of a coding region, if present, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, introns, 5’ - and 3 ’-untranslated regions, and the like, are not part of a coding region.
  • Two or more coding regions can be present in a single polynucleotide construct, e.g., on a single vector, or in separate polynucleotide constructs, e.g., on separate (different) vectors.
  • any vector may contain a single coding region, or may comprise two or more coding regions, e.g., a vector of the present invention may encode one or more polypeptides, which are post- or co-translationally separated into the final proteins via proteolytic cleavage.
  • a vector, polynucleotide, or nucleic acid of the invention may encode heterologous coding regions, either fused or unfused to a polynucleotide encoding the fusion protein (fragment) of the invention, or variant or derivative thereof.
  • Heterologous coding regions include without limitation specialized elements or motifs, such as a secretory signal peptide or a heterologous functional domain.
  • An operable association is when a coding region for a gene product, e.g., a polypeptide, is associated with one or more regulatory sequences in such a way as to place expression of the gene product under the influence or control of the regulatory sequence(s).
  • Two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are “operably associated” if induction of promoter function results in the transcription of mRNA encoding the desired gene product and if the nature of the linkage between the two DNA fragments does not interfere with the ability of the expression regulatory sequences to direct the expression of the gene product or interfere with the ability of the DNA template to be transcribed.
  • a promoter region would be operably associated with a nucleic acid encoding a polypeptide if the promoter was capable of effecting transcription of that nucleic acid.
  • the promoter may be a cell-specific promoter that directs substantial transcription of the DNA only in predetermined cells.
  • Other transcription control elements besides a promoter, for example enhancers, operators, repressors, and transcription termination signals, can be operably associated with the polynucleotide to direct cell-specific transcription. Suitable promoters and other transcription control regions are disclosed herein. A variety of transcription control regions are known to those skilled in the art.
  • transcription control regions which function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegaloviruses (e.g., the immediate early promoter, in conjunction with intron- A), simian virus 40 (e.g., the early promoter), and retroviruses (such as, e.g., Rous sarcoma virus).
  • transcription control regions include those derived from vertebrate genes such as actin, heat shock protein, bovine growth hormone and rabbit a-globin, as well as other sequences capable of controlling gene expression in eukaryotic cells.
  • tissue-specific promoters and enhancers as well as inducible promoters (e.g., promoters inducible tetracyclins).
  • inducible promoters e.g., promoters inducible tetracyclins
  • translation control elements include, but are not limited to ribosome binding sites, translation initiation and termination codons, and elements derived from viral systems (particularly an internal ribosome entry site, or IRES, also referred to as a CITE sequence).
  • the expression cassette may also include other features such as an origin of replication, and/or chromosome integration elements such as retroviral long terminal repeats (LTRs), or adeno-associated viral (AAV) inverted terminal repeats (ITRs).
  • LTRs retroviral long terminal repeats
  • AAV adeno-associated viral inverted terminal repeats
  • Fusion proteins prepared as described herein may be purified by art-known techniques such as high-performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like.
  • the actual conditions used to purify a particular protein will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity etc., and will be apparent to those having skill in the art.
  • affinity chromatography purification an antibody, ligand, receptor or antigen can be used to which the fusion protein binds.
  • the purity of the fusion protein can be determined by any of a variety of well-known analytical methods including gel electrophoresis, high pressure liquid chromatography, and the like.
  • the nucleic acid encoding the fusion protein may be expressed as a single nucleic acid molecule that encodes the entire fusion protein or as multiple (e.g., two or more) nucleic acid molecules that are co-expressed. Polypeptides encoded by nucleic acid molecules that are co-expressed may associate through, e.g., disulfide bonds or other means, to form a functional fusion protein.
  • the fusion protein is a triple fusion protein, i.e., the fusion protein comprises the transposase or the fragment thereof, and at least two additional polypeptides or proteins.
  • the fusion protein further comprises a nuclear localization sequence (NLS).
  • NLS nuclear localization sequence
  • one or more NLS should have sufficient strength to drive the accumulation of the fusion protein in the nucleus of the cell.
  • the strength of the nuclear localization activity is determined by the number and position of NLSs, and one or more specific NLSs used in the fusion protein.
  • the NLSs may be located at the N-terminus and/or the C-terminus of the fusion protein.
  • the fusion protein comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs.
  • the fusion protein comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the N-terminus.
  • the fusion protein comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the C-terminus.
  • the fusion protein comprises a combination of these, such as one or more NLSs at the N-terminus and one or more NLSs at the C-terminus.
  • each NLS may be selected as independent from other NLSs.
  • the fusion protein comprises two NLSs, for example, the two NLSs are located at the N-terminus and the C-terminus, respectively.
  • an NLS consists of one or more short sequences of positively charged lysine or arginine exposed on the surface of a protein, but other types of NLS are also known in the art.
  • NLSs include (M)KKRKV (with SEQ ID NO: 52), (M)PKKKRKV (with SEQ ID NO: 53), or (M)SGGSPKKKRKV (with SEQ ID NO: 54), wherein (M) denotes an initiator methionine which may be present when the NLS is located in N-terminal or be post-translationally removed, and which is absent when the NLS is located in C-terminal.
  • the fusion protein may also include other localization sequences, such as cytoplasmic localization sequences, chloroplast localization sequences, mitochondrial localization sequences, and the like, depending on the desired localization of the fusion protein in a cell.
  • localization sequences such as cytoplasmic localization sequences, chloroplast localization sequences, mitochondrial localization sequences, and the like, depending on the desired localization of the fusion protein in a cell.
  • the at least one additional polypeptide or protein is a nuclease.
  • the nuclease is an endonuclease or an exonuclease.
  • the nuclease is a deoxyribonuclease or a ribonuclease.
  • the at least one additional polypeptide or protein is an RNA-guided nuclease.
  • the at least one additional polypeptide or protein is a Cas nuclease.
  • the Cas nuclease is selected from the group comprising or consisting of Cas9, Casl2a (Cpfl), Casl2b, Casl2f, and CasX. It shall be understood that variants and functional fragments thereof are also encompassed, such as nickase Cas (nCas) or dead Cas (dCas) variants.
  • Cas9 nucleases include, without limitation, Streptococcus pyogenes Cas9 (SpCas9), Staphylococcus haemolyticus Cas9 (ShCas9), and Campylobacter jejuni Cas9 (CjCas9).
  • the Cas nuclease has at least 80 %, 85 %, 90 %, 95 %, 99 % or more amino acid sequence identity with the sequence of SpCas9 with SEQ ID NO: 27, ShCas9 with SEQ ID NO: 28, Cpfl with SEQ ID NO: 29, CjCas9 with SEQ ID NO: 30, nCas9 with SEQ ID NO: 31, and/or nCas9 with SEQ ID NO: 32.
  • the Cas nuclease has at least 80 %, 85 %, 90 %, 95 %, 99 % or more amino acid sequence identity with the amino acid sequence of ShCas9 with SEQ ID NO: 28 or SpCas9 with SEQ ID NO: 27.
  • the Cas nuclease is ShCas9 with SEQ ID NO: 28. In some embodiments, the Cas nuclease is SpCas9 with SEQ ID NO: 27.
  • the at least one additional polypeptide or protein is a variant or a functional fragment of a Cas9 nuclease.
  • a Cas9 variant typically comprises one or several amino acid substitutions as compared to the wild-type amino acid sequence of said Cas9.
  • the Cas9 variant is humanized Cas9 (hCas9) or a functional fragment thereof.
  • the term “humanized Cas9” or “hCas9” refers to an optimized Cas9 protein sequence for expression in human cells.
  • hCas9 has an amino acid sequence having at least 80 %, 85 %, 90 %, 95 %, 99 % or more amino acid sequence identity with the amino acid sequence of SEQ ID NO: 33. In some embodiments, hCas9 has an amino acid sequence consisting of SEQ ID NO: 33.
  • the at least one additional polypeptide or protein is CasX.
  • CasX has an amino acid sequence having at least 80 %, 85 %, 90 %, 95 %, 99 % or more amino acid sequence identity with the amino acid sequence of SEQ ID NO: 34.
  • CasX has an amino acid sequence consisting of SEQ ID NO: 34.
  • the at least one additional polypeptide or protein is a dead Cas9 protein (dCas9).
  • dCas9 has an amino acid sequence having at least 80 %, 85 %, 90 %, 95 %, 99 % or more amino acid sequence identity with the amino acid sequence of SEQ ID NO: 35.
  • dCas9 has an amino acid sequence consisting of SEQ ID NO: 35.
  • the at least one additional polypeptide or protein is TnpB (Transposase B from transposon PsiTn554).
  • TnpB has an amino acid sequence having at least 80 %, 85 %, 90 %, 95 %, 99 % or more amino acid sequence identity with the amino acid sequence of SEQ ID NO: 36.
  • TnpB has an amino acid sequence consisting of SEQ ID NO: 36.
  • the at least one additional polypeptide or protein is Casl2f.
  • Casl2f protein is from the bacterium Acidibacillus sulfuroxidans (AsCasl2f).
  • Casl2f has an amino acid sequence having at least 80 %, 85 %, 90 %, 95 %, 99 % or more amino acid sequence identity with the amino acid sequence of SEQ ID NO: 37.
  • Casl2f has an amino acid sequence consisting of SEQ ID NO: 37.
  • the protein or polypeptide comprising the transposase or a fragment thereof is a fusion protein comprising the transposase or a fragment thereof, and a nuclease as described hereinabove.
  • the fusion protein has at least 75 %, 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % or more amino acid sequence identity with SEQ ID NO: 2. In some embodiments, the fusion protein comprises or consists of the amino acid sequence of SEQ ID NO: 2.
  • the at least one additional polypeptide or protein is an aptamer-binding protein.
  • the at least one additional polypeptide or protein is an aptamer-binding protein selected from the group comprising or consisting of MS2 bacteriophage coat protein (MCP), PP7 coat protein (PCP), XN22 peptide and COM.
  • the at least one additional polypeptide or protein is the MS2 bacteriophage coat protein (MCP).
  • MCP has an amino acid sequence having at least 80 %, 85 %, 90 %, 95 %, 99 % or more amino acid sequence identity with the amino acid sequence of SEQ ID NO: 39.
  • MCP is capable of binding to a MS2 RNA tetraloop binding sequence (or “MS2 aptamer”).
  • MS2 aptamer has a nucleic acid sequence having at least 80 %, 85 %, 90 %, 95 %, 99 % or more amino acid sequence identity with the amino acid sequence of SEQ ID NO: 40.
  • the fusion protein interacts, or is capable of interacting, covalently or non-covalently through MCP with a guide RNA (gRNA) molecule comprising at least one MS2 aptamer.
  • gRNA guide RNA
  • the method of the invention may further comprise contacting the cell population with a guide RNA (gRNA) fused to at least one aptamer.
  • gRNA guide RNA
  • the aptamer is an RNA sequence comprising a tetraloop.
  • tetraloop refers to a four-base hairpin loop motif. The term is used interchangeably herein with the terms “stem loop” or “hairpin loop”.
  • the aptamer is a MS2 RNA tetraloop sequence (or MS2 aptamer).
  • the MS2 aptamer has a nucleic acid sequence having at least 80 %, 85 %, 90 %, 95 %, 99 % or more amino acid sequence identity with the amino acid sequence of SEQ ID NO: 40.
  • the aptamer comprises or consists of the nucleic acid sequence with SEQ ID NO: 40.
  • the gRNA is capable of forming a complex with an RNA-guided nuclease as described hereinabove, e.g., a Cas protein or fusion protein comprising a Cas protein.
  • the gRNA molecule interacts, or is capable of interacting, covalently or non-covalently through the at least one MS2 aptamer with an RNA-guided nuclease.
  • the gRNA is capable of targeting the RNA-guided nuclease as described hereinabove to a specific sequence or region of the genome of a cell, preferably a mammalian cell, more preferably a human cell.
  • the specific sequence targeted by the gRNA is adjacent to a protospacer adjacent motif (PAM) specific for the Cas protein.
  • PAM protospacer adjacent motif
  • the specific sequence targeted by the gRNA may be within a safe harbor locus in a cell’s genome.
  • a “safe harbor locus” refers to a region of a cell’s genome, where the integrated material can be adequately expressed without perturbing endogenous gene structure or function. Safe harbor loci include, but are not limited to, AAVS1 (intron 1 of PPP1R12C), HPRT, HI 1, hRosa26, albumin and F-A region.
  • the safe harbor locus may be an exon or an intron of a ubiquitously expressed gene and/or of a gene with tissue specific expression (e.g., muscle).
  • Safe harbor loci can be selected from the group consisting of: exon 1, intron 1 or exon 2 of PPP1R12C; exon 1, intron 1 or exon 2 of HPRT; exon 1, intron 1 or exon 2 of hRosa26; or intron 1 of the albumin gene.
  • a safe harbor locus may also include a region of the genome devoid of endogenous genes and with open chromatin that allows for the expression of the inserted transgene without perturbing the genome structure or function.
  • the gRNA comprises 20, 25, 30, 35, 40, 45, 50 nucleotides or more.
  • the protein or polypeptide comprising the transposase or the fragment thereof is delivered to the cell in the form of a protein.
  • the protein or polypeptide comprising the transposase or the fragment thereof is delivered to the cell in the form of a nucleic acid encoding said transposase or fragment thereof.
  • the nucleic acid may be a ribonucleic acid (RNA) or a deoxyribonucleic acid (DNA).
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is an RNA molecule. In some embodiments, the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is a messenger RNA (mRNA) molecule.
  • mRNA messenger RNA
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof may be a DNA molecule.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is a complementary DNA (cDNA).
  • the DNA molecule may be comprised within a vector, such as, e.g., a plasmid.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is linear or circular. In some embodiments, the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is double-stranded or single-stranded.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population by transfection or transformation.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population by transfection.
  • transfection techniques include, without limitation, lipofection, electroporation, sonication, nanoparticles, microinjection and viral vector infection, including non-integrative and integrative viral vector infection.
  • transfection is performed by lipofection.
  • Means of performing lipofection are known in the part and comprise using a lipofection reagent such as, e.g., lipofectamineTM.
  • transfection is performed by electroporation.
  • transfection is performed by sonication.
  • transfection is performed by nanoparticles (e.g., polymeric nanoparticles such as JetPEI).
  • transfection is performed by microinjection.
  • transfection is performed by viral vector infection.
  • the viral vector is integrative or non-integrative, preferably non-integrative. Non-limitative examples of non-integrative viral vectors include adenoviral vectors, adeno-associated virus (AAV) vectors, poxviral vectors, herpes simplex virus vectors and the like.
  • AAV adeno-associated virus
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population by transformation.
  • transformation techniques include, without limitation, the use of an integrative vector selected from the group comprising or consisting of integrating viral vectors, integrating plasmids, enzymes or genome editing methods.
  • transformation comprises using an integrative viral vector or a modified integrative virus.
  • the integrative viral vector or a modified integrative virus is an integrating virus or variant thereof or mutant thereof selected from the group comprising or consisting of the Retroviridae, Adenoviridae, Flaviviridae, Herpesviridae, Hepadnaviridae, Papillomaviridae, Polyomaviridae, Parvoviridae, Arenaviridae, Bornaviridae, Bunyaviridae, Filoviridae and Paramyxoviridae families of viruses, preferably selected from the group comprising or consisting of the Retroviridae, Adenoviridae and Flaviviridae families of viruses.
  • the integrative viral vector belongs to the family of Retroviridae .
  • the integrative viral vector is a lentivirus, or a modified lentivirus.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population together with the nucleic acid molecule encoding the at least one transgene of interest.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof, and the nucleic acid molecule encoding the at least one transgene of interest are delivered in the same vector.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof, and the nucleic acid molecule encoding the at least one transgene of interest are delivered concomitantly in separate vectors.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population prior to the nucleic acid molecule encoding the at least one transgene of interest, such as, e.g., 1, 2, 3, 4, 5, 10, 30, 60 minutes, 2, 3, 4, 5, 6, 12, 24, 36, 48, 60, 72 hours, 4, 5, 6, 7 days or more before the nucleic acid molecule encoding the at least one transgene of interest.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population from
  • nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population from
  • 2 hours to 72 hours from 3 hours to 72 hours, from 4 hours to 72 hours, from 5 hours to 72 hours, from 6 hours to 72 hours, from 7 hours to 72 hours, from 8 hours to 72 hours, from 9 hours to 72 hours, from 10 hours to 72 hours, from 11 hours to 72 hours, from 12 hours to 72 hours, from 24 hours to 72 hours, from 36 hours to 72 hours, from 48 hours to 72 hours before the nucleic acid molecule encoding the at least one transgene of interest.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population from 1 hour to 60 hours, from 1 hour to 48 hours, from 1 hour to 36 hours, from 1 hour to 24 hours, from 1 hour to 12 hours, from 1 hour to 11 hours, from 1 hour to 10 hours, from
  • 1 hour to 9 hours from 1 hour to 8 hours, from 1 hour to 7 hours, from 1 hour to 6 hours, from 1 hour to 5 hours, from 1 hour to 4 hours, from 1 hour to 3 hours, from 1 hour to
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population from 1 hour to 12 hours, from 2 hours to 8 hours, from 3 hours to 6 hours before the nucleic acid molecule encoding the at least one transgene of interest.
  • the nucleic acid encoding the protein or polypeptide comprising a transposase or a fragment thereof is delivered to the cell population about 4 hours before the nucleic acid molecule encoding the at least one transgene of interest.
  • the protein or polypeptide comprising a transposase or a fragment thereof, or the nucleic acid encoding the same is comprised in a pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient.
  • the term “pharmaceutically acceptable excipient” refers to an excipient that does not produce an adverse, allergic or other untoward reaction when administered to an animal, preferably a human, or to a population of cells. It includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • An acceptable excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • preparations should meet sterility, pyrogenicity, general safety and purity standards as required by EMA or FDA Office of Biologies standards.
  • the acceptable excipient is selected in a group comprising or consisting of a solvent, a diluent, a carrier, a dispersion medium, a coating, an antibacterial agent, an antifungal agent, an isotonic agent, an absorption delaying agent and any combinations thereof.
  • the excipient must be “acceptable” in the sense of being compatible with the protein, polypeptide or nucleic acid molecule of the method, and not be deleterious upon being administered to an individual or to a population of cells.
  • the excipient does not produce an adverse, allergic or other untoward reaction when administered to an individual, preferably a human individual, or to a population of cells.
  • the cell population is a population of eukaryotic cells or of prokaryotic cells. In some embodiments, the cell population is a eukaryotic cell population. In some embodiments, the cell population is a prokaryotic cell population.
  • the cell population is isolated from a donor.
  • donor refers to an animal, preferably a mammal, more preferably a human. The donor may be alive or dead when the cell population is isolated, preferably alive.
  • the cell population is isolated from at least one organ or tissue of the donor, optionally from more than one organ or tissue of the donor.
  • the cell population is homogeneous (z.e., it contains a single type of cells) or heterogenous (z.e., it contains more than one type of cells), preferably homogenous.
  • the cell population is cultured in vitro. In some embodiments, the cell population is comprised in a primary cell culture.
  • the cell population is from an immortalized cell line.
  • the method is performed in vitro.
  • the cell population is an in vztro-cultured population of cells.
  • the cell population is cultured from 2 hours to 72 hours, from 3 hours to 72 hours, from 4 hours to 72 hours, from 5 hours to 72 hours, from 6 hours to 72 hours, from 7 hours to 72 hours, from 8 hours to 72 hours, from 9 hours to 72 hours, from 10 hours to 72 hours, from 11 hours to 72 hours, from 12 hours to 72 hours, from 24 hours to 72 hours, from 36 hours to 72 hours, from 48 hours to 72 hours.
  • a controlled atmosphere e.g., 37°C, 5 % CO2
  • suitable culture medium e.g., Dulbecco’s Modified Eagle Medium.
  • the cell population is cultured from 2 hours to 72 hours, from 3 hours to 72 hours, from 4 hours to 72 hours, from 5 hours to 72 hours, from 6 hours to 72 hours, from 7 hours to 72 hours, from 8 hours to 72 hours, from 9 hours to 72 hours, from 10 hours to 72 hours, from 11 hours to 72 hours, from 12 hours to 72 hours, from 24 hours to 72 hours, from 36 hours to 72 hours, from 48 hours to 72 hours.
  • the cell population is cultured from 1 hour to 60 hours, from 1 hour to 48 hours, from 1 hour to 36 hours, from 1 hour to 24 hours, from 1 hour to 12 hours, from 1 hour to 11 hours, from 1 hour to 10 hours, from 1 hour to 9 hours, from 1 hour to 8 hours, from 1 hour to 7 hours, from 1 hour to 6 hours, from 1 hour to 5 hours, from 1 hour to 4 hours, from 1 hour to 3 hours, from 1 hour to 2 hours.
  • the cell population is a non-dividing, non-replicating, terminally differentiated or quiescent, cell population.
  • non-dividing cell population non-replicating cell population
  • terminal differentiated quiescent cell population
  • non-dividing cell means that the cell remains out of the cell cycle but retains the capacity to divide, in other words, the cell is in a state of reversible growth arrest.
  • Quiescence may be induced by, non-imitatively, contact inhibition, chemical or pharmacological agents, signaling proteins, hormones, inhibitors, and the like, or, alternatively, by the lack of a signal such as a growth factor or the contact with one or more cell types.
  • the cell population is quiescent in the presence of one or more growth inhibiting agent in the culture medium.
  • the one or more growth inhibiting agent is selected from the group comprising or consisting of chemical agents, pharmacological agents, signaling proteins, hormones, growth factors, and inhibitors.
  • the cell population is quiescent in the absence of one or more growth stimulating agent in the culture medium.
  • the one or more growth stimulating agent is selected from the group comprising or consisting of chemical agents, pharmacological agents, signaling proteins, hormones, growth factors, amino acids, sugars, lipids, and fatty acids.
  • “terminally differentiated” cell means that the cell remains out of the cell cycle and lost the capacity to divide, in other words, the cell is in a state of irreversible growth arrest.
  • the non-dividing or quiescent cell population is a confluent cell culture (z.e., quiescence is induced by contact inhibition).
  • the non-dividing or quiescent cell population consists of at least one cell type that do not replicate in culture.
  • the non-dividing or quiescent cell population is senescent.
  • the non-dividing or terminally differentiated cell population consists of at least one cell type that have completely lost the capacity to perform cell division.
  • the cell population is not actively dividing.
  • the cell population is actively dividing, replicating, or proliferating. In some embodiments, the dividing cell population is in exponential phase of cell culture.
  • the method is performed ex vivo.
  • the method is performed in vivo. In some embodiments, the method is performed in vivo in an animal subject, preferably a mammal subject. In certain embodiments, the method is performed in vivo in a human subject. In some embodiments, the cell population is comprised in a tissue or an organ of a living organism. In some embodiments, the organism is an animal. In some embodiments, the organism is a mammal. In some embodiments, the organism is a human.
  • the present invention further relates to a cell or cell population comprising at least one copy of a protein or polypeptide comprising a transposase or a fragment thereof, or a nucleic acid encoding the same, and/or at least one copy of at least one transgene of interest.
  • a cell or cell population comprises both at least one copy of a protein or polypeptide comprising a transposase or a fragment thereof, or a nucleic acid encoding the same, and at least one copy of at least one transgene of interest.
  • the protein or polypeptide comprising a transposase or a fragment thereof, or the nucleic acid encoding the same, the at least one transgene of interest, and the cell or cell population further comprise the features as disclosed hereinabove.
  • the present invention further relates to a method of treating a genetic disease in a subject in need thereof, comprising administering to said subject: the nucleic acid molecule encoding the at least one transgene of interest, as described hereinabove, and a protein or polypeptide comprising a transposase or a fragment thereof, or a nucleic acid encoding the same, as described hereinabove.
  • nucleic acid molecule encoding the at least one transgene of interest, as described hereinabove, and the protein or polypeptide comprising a transposase or a fragment thereof, or a nucleic acid encoding the same, as described hereinabove, for use in treating a genetic disease in a subject in need thereof.
  • nucleic acid molecule encoding the at least one transgene of interest, as described hereinabove, and the protein or polypeptide comprising a transposase or a fragment thereof, or a nucleic acid encoding the same, as described hereinabove, for the manufacture of a medicament for treating a genetic disease in a subject in need thereof.
  • the transgene of interest compensates for a gene detect responsible of the genetic disease in the subject.
  • the method further comprises administering to the subject a guide RNA (gRNA) fused to at least one aptamer, as described hereinabove.
  • gRNA guide RNA
  • the method may comprise administering to the subject in need thereof at least one additional therapeutic agent.
  • the at least one therapeutic agent is for treating the genetic disease.
  • the genetic disease is characterized in that at least one gene is mutated in the genome of the subject, so that the protein encoded by the at least one gene has impaired function or is not functional, or is degraded by the cellular protein quality control (e.g., proteasome), or is not produced; in other words, the function of the at least one gene is at least partially, if not completely lost.
  • the cellular protein quality control e.g., proteasome
  • Non-limitative examples of genetic diseases include sickle cell anemia, cystic fibrosis, Huntington disease, congenital muscular dystrophy, Duchenne muscular dystrophy, Fabry disease, Marfan syndrome, thalassemia, cystinosis, familial hypercholesterolemia, hemochromatosis and the like.
  • the transgene of interest restores partially or completely, preferably completely, the function of the at least one gene that is mutated. In some embodiments, the transgene of interest encodes the same protein as the at least one gene that is mutated. In some embodiments, the transgene of interest encodes a different protein than the one encoded the at least one gene that is mutated, but that has similar or identical biological function.
  • Figure 1 is a set of photographs illustrating the viability and transfection efficiency of GFP expressing transposon and transposase in Embryonic stem cells H9 electroporated with transposases (either hyPB alone or fused with a Cas9 nuclease).
  • BF Bright Field
  • GFP Green Fluorescent Protein.
  • Figure 3 is a histogram showing the transcription efficiency of a RFP reporter in Huh7 cells expressing or not hyPB.
  • Figures 4 and 5 are graphs showing the transcription efficiency over time (at 3h, 6h, 9h, and 12h in Figure 4; at 8h, lOh, 12h, 14h and 16h in Figure 5) of a GFP reporter in Huh7 cells expressing or not hyPB.
  • Figure 6 is a histogram showing the transcription efficiency of a GFP reporter in Huh7 cells expressing or not a catalytically dead hyPB.
  • Figure 7 is a histogram showing the transcription efficiency of a GFP reporter in Huh7 cells expressing a fusion protein comprising a Cas9 nuclease and either a SB 100 transposase or a N57 transposase.
  • Figures 8A-8B is a set of histograms comparing the transcription efficiency of a GFP reporter in Huh7 cells expressing or not hyPB, wherein the GFP DNA transposon comprises either one Inverted Terminal Repeat (ITR) ( Figure 8A) or two ITRs ( Figure 8B).
  • ITR Inverted Terminal Repeat
  • Figure 9 is a set of photographs showing the transcription efficiency of a luciferase reporter in vivo in mice, one day or 4 weeks after injection, with either hyPB mRNA or a catalytically dead hyPB mRNA.
  • Figure 10 is a set of photographs showing the transcription efficiency of a luciferase reporter in vivo, one day or one week after injection, in mice transfected or not with hyPB DNA using a polymeric nanoparticle vector (jetPEI).
  • jetPEI polymeric nanoparticle vector
  • Figure 11 is a set of photographs showing the transcription efficiency of a luciferase reporter in vivo, one day after injection, in mice transfected or not with hyPB and wherein the DNA payload (luciferase reporter) and the hyPB mRNA are co transfected using the same vector (lipid nanoparticles).
  • Embryonic Stem Cells H9 were electroporated (CRG cell and tissue facility) with 1.8 pg of minicircle GFP transposon alone or together with 1 pg hyPB mRNA or 1.5 pg FiCAT mRNA and 1.75 pg of sgRNA targeting AAVS1 locus. Cells were imaged in a fluorescent microscope and using bright field and viability and % of GFP signal was estimated.
  • Day 0 400k cells/well were seeded in p6 well plates.
  • Day 1 1.25 pg of either hyPB plasmid or pucl9 mock plasmid were transfected with lipofectamine 3000 according manufacturer’s protocol. Cells were kept during 2h with Optimem + transfection mix, and then full media was added (Dulbecco’s modified Eagle medium 10 % fetal bovine serum, 2 mM glutamine and 100 U penicillin/0.1 mg/ml streptomycin)
  • Day 3 Cells were transfected with 0.75 pg RFP DNA transposon and 0.25 pg pucl9 filling DNA with lipofectamine 3000 according manufacturer’s protocol. Cells were kept during 2 hours with Optimem + transfection mix, and then full media was added.
  • the cells were transfected on day 1 with Cas9_SB100 plasmid and Cas9_N57 plasmid instead of hyPB.
  • cells were transfected with GFP transposon containing SB 100 ITRs and with TCR1 gRNA plasmid.
  • 400,000 cells were seeded 24h before transfection in p6 wells. Transfection was performed using 1.8 pg transposon DNA and 1.95 pg hyPB or mock mRNA of similar size with lipofectamine 3000 according manufacturer’s protocol. Cells were kept during 2 hours with Optimem + transfection mix, and then full media was added. Cells were lifted every 3 hours or every 14 hours post-transfection and fluorescence was measured by flow cytometry.
  • the cells were transfected on day 1 with Cas9_SB100 plasmid and Cas9_N57 plasmid instead of hyPB.
  • cells were transfected with GFP transposon containing SB 100 ITRs and with TCR1 gRNA plasmid.
  • nucleic acids were injected into 6-7 weeks old mice (3.2 pg MC-luciferase transposon, 1.42 pg hyPB/hyPB_dead mRNA). Nucleic acids were diluted with PBS and 7 % of animal body weight in ml was injected in less than 7 seconds via retro-orbital systemic injection.
  • Lipid proportions were 50 % Dlin-MC3, 10 % DSPC helper lipid, 38.5 % cholesterol, 1.5 % PEG-2000 and N/P ratio of 6. Size of the nanoparticles were 100-130 nm and encapsulation efficiencies higher than 90 %.
  • Embryonic Stem Cells H9 electroporated with transposases shows GFP signal ( Figure 1), meaning that GFP transposon DNA has entered the nucleus and it has been translated and transcribed. While episomal signal of GFP transposon without hyPB or FiCAT is low (20 % efficiency), hyPB yields a stronger GFP signal (70 % transfection efficiency).
  • HepG2 hepatic cell line previously expressing hyPB shows better internalization of RFP DNA transposon than cells which do not express hyPB ( Figure 2). This result was also obtained with Huh7 hepatic cell line ( Figure 3).
  • Huh7 cells transfected with hyPB mRNA show higher capacity for uptake and expression of DNA transposon compared to cells transfected with mock mRNA ( Figures 4 & 5).
  • Huh7 hepatic cell line transfected with hyPB catalytically dead mRNA shows higher capacity for nuclear uptake and expression of DNA transposon compared to cells transfected with mock mRNA ( Figure 6).
  • hyPB transposases show advantages in DNA payload internalization and expression, even if its catalytic activity is compromised (dead hyPB). 1 out of 3 mice shows luciferase expression 24h after hydrodynamic injection of solo payload while this increases to 2/3 or 3/3 mice when co-injected with hyPB or hyPB catalytically dead.
  • hyPB transposases show advantages in DNA payload internalization and expression, when payload DNA and hyPB mRNA are administered using different delivery methods ( Figure 10).
  • Figure 10 When injecting DNA, 50 % of mice shows luciferase signal 24h after while 100 % of mice shows signal when co-administering hyPB using LNPs.
  • hyPB transposases show advantages in DNA payload internalization and expression, when payload DNA and hyPB mRNA are administered using the same delivery methods ( Figure 11). When injecting DNAsolo, mice do not show luciferase signal while signal is recovered when co-administering hyPB using LNPs in both cases. This result shows hyPB helps internalize DNA into the nucleus therefore it can be expressed.
  • Example 2 Nuclear localization in non-dividing cells
  • NIH/3T3 (ATCC), were cultured in DMEM supplemented with 10 or 1% heat- inactivated fetal bovine serum, lOO U/ml penicillin and O. l mg/ml streptomycin in a humidified CO2 (5%) incubator at 37°C.
  • liver perfusion buffer HBSS KC1 0.4 g.L glucose 1 g.L 1 , NaHCO3 2.1 g.L 1 , EDTA 0.2 g.L 1
  • liver digest buffer DMEM-GlutaMAX 1 g.L 1 glucose, HEPES 15 mM pH 7.4, penicillin/streptomycin 1%, 5 mg per mouse Collagenase IV (C5138 Sigma)
  • liver was placed on ice in plating media (M199, fetal bovine serum 10%, penicillin/streptomycin 1%, sodium pyruvate 1%, L-glutamine 1%, 1 nm insulin, 1 mM dexamethasone, 2 mg.mL 1 bovine serum albumin (BSA)).
  • BSA bovine serum albumin
  • hepatocytes were isolated from a wild-type 8-weeks old mouse, and 75.000 cells were seeded per well. After 48h in culture, cells were transfected. Transfection was performed using 0.2 ug transposon DNA alone (Episomal) or in combination with 0.25ug of hyPB-wt or a catalytically dead hyPB (dead-hyPB) with lipofectamine 3000 according to manufacturer’s protocol. Cells were incubated for 5 hours with the transfection mix in Optimem, and then full media was added. 24 hours after transfection, cells were washed once with PBS and lysated with the appropriate buffer.
  • Luciferase activities were quantified 24h post-transfection using the Luciferase assay system (Promega, Madison, WI, USA), performed in duplicated. Data is shown as fold change over to the non-transfected hepatocytes luciferase values, and expressed in Arbitrary units (AU).
  • FIG. 12 shows that uptake and expression of the DNA transposon (GFP) is increased in cells expressing hyPB or dead-hyPB, even with the lowest dose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés d'augmentation de l'expression d'un transgène d'intérêt dans une population cellulaire et/ou d'augmentation de la localisation nucléaire d'un transgène d'intérêt dans une population cellulaire, à l'aide d'une transposase.
EP23726939.4A 2022-05-13 2023-05-12 Utilisation de transposases pour améliorer l'expression transgénique et la localisation nucléaire Pending EP4522735A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341619P 2022-05-13 2022-05-13
EP22191966 2022-08-24
PCT/EP2023/062736 WO2023218021A1 (fr) 2022-05-13 2023-05-12 Utilisation de transposases pour améliorer l'expression transgénique et la localisation nucléaire

Publications (1)

Publication Number Publication Date
EP4522735A1 true EP4522735A1 (fr) 2025-03-19

Family

ID=86605260

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23726939.4A Pending EP4522735A1 (fr) 2022-05-13 2023-05-12 Utilisation de transposases pour améliorer l'expression transgénique et la localisation nucléaire

Country Status (7)

Country Link
EP (1) EP4522735A1 (fr)
JP (1) JP2025518638A (fr)
KR (1) KR20250010025A (fr)
CN (1) CN119487184A (fr)
AU (1) AU2023269540A1 (fr)
CA (1) CA3253152A1 (fr)
WO (1) WO2023218021A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027384A1 (fr) * 2006-08-28 2008-03-06 University Of Hawaii Procédés et compositions pour transgénèse induite par transposon
MA50877A (fr) * 2017-11-21 2020-09-30 Bayer Healthcare Llc Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
EP3898967A1 (fr) * 2018-12-17 2021-10-27 Consejo Superior de Investigaciones Científicas (CSIC) Procédé d'introduction d'informations génétiques dans une cellule par un système d'intégration spécifique de site
WO2020243085A1 (fr) 2019-05-24 2020-12-03 The Trustees Of Columbia University In The City Of New York Système de transposon de cas modifié pour des transpositions d'adn programmable et dirigées sur un site
CN115968301A (zh) * 2020-04-20 2023-04-14 综合Dna技术公司 优化的蛋白融合和接头
WO2021248023A2 (fr) * 2020-06-05 2021-12-09 The Regents Of The University Of California Compositions et procédés pour l'édition de l'épigénome
CA3173696A1 (fr) * 2020-07-17 2022-01-20 Volker Sandig Transposons et transposases hyperactifs
WO2022129438A1 (fr) 2020-12-16 2022-06-23 Universitat Pompeu Fabra Transposases programmables et utilisations associées

Also Published As

Publication number Publication date
WO2023218021A1 (fr) 2023-11-16
CA3253152A1 (fr) 2023-11-16
JP2025518638A (ja) 2025-06-18
KR20250010025A (ko) 2025-01-20
AU2023269540A1 (en) 2024-11-07
CN119487184A (zh) 2025-02-18

Similar Documents

Publication Publication Date Title
US20240167060A1 (en) Compositions and methods for genomic editing by insertion of donor polynucleotides
US10927383B2 (en) Cas9 mRNAs
CA3036926C (fr) Cellules t de memoire de cellules souches modifiees, procedes de fabrication et procedes d'utilisation correspondants
AU2018338790B2 (en) Non-human animals comprising a humanized TTR locus and methods of use
JP2025066771A (ja) サプレッサーｔＲＮＡ及びデアミナーゼによる変異のＲＮＡターゲティング
CN114007655A (zh) 用于细胞疗法的环状rna
KR102738651B1 (ko) 간에서 목적하는 단백질 발현하기 위한 플랫폼
KR20200032693A (ko) Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
KR102915369B1 (ko) X-연관 연소 망막층간분리 치료법을 위한 crispr 및 aav 전략
US12448630B2 (en) CRISPR-Cas systems and uses thereof
WO2023193616A1 (fr) Procédé de réparation de mutations du gène hba2 par édition de base unique et son utilisation
CN110891419A (zh) 评价crispr/cas-诱导的与外源供体核酸的体内重组
CN118632622A (zh) 突变型肌纤蛋白疾病模型及其用途
EP3640334A1 (fr) Système d'édition de génome pour une mutation de type expansion de répétition
EP4522735A1 (fr) Utilisation de transposases pour améliorer l'expression transgénique et la localisation nucléaire
US20250269057A1 (en) Therapeutic lama2 payload for treatment of congenital muscular dystrophy
US20220411826A1 (en) Co-opting regulatory bypass repair of genetic diseases
RU2784927C1 (ru) Отличные от человека животные, включающие в себя гуманизированный ttr локус, и способы применения
WO2026059836A1 (fr) Nanoparticules lipidiques et leurs procédés d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20241213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)